Bay Area liquid‑biopsy developer Freenome agreed to go public through a $330 million SPAC merger with Perceptive Capital Solutions Corp., backed by a roughly $240 million PIPE from investors including Perceptive Advisors and RA Capital. The company said proceeds will support a planned 2026 commercialization of SimpleScreen, a blood‑based colorectal and multi‑cancer screening test currently under FDA review. Freenome touted pivotal PREEMPT CRC data and a recent JAMA publication as clinical validation for SimpleScreen and highlighted commercialization partnerships in its investor communications. If approved, the test would compete in an increasingly crowded MCED (multi‑cancer early detection) market alongside Guardant and others. Clarification: MCED blood tests profile circulating biomarkers to screen for multiple cancers from a single blood draw; regulatory clearance, reimbursement, and clinical‑utility evidence remain central commercialization hurdles.